Abstract
In 2011, key trials with oral factor Xa inhibitors in patients with atrial fibrillation highlighted promising data on these novel anticoagulants. Patients with ≥ 1 stroke risk factors can be considered for oral anticoagulation. These novel, fixed-dose drugs are given without monitoring, so clinicians must learn to balance stroke and bleeding risks.
MeSH terms
-
Administration, Oral
-
Anticoagulants / administration & dosage
-
Anticoagulants / therapeutic use*
-
Atrial Fibrillation* / complications
-
Atrial Fibrillation* / drug therapy
-
Atrial Fibrillation* / physiopathology
-
Dose-Response Relationship, Drug
-
Factor Xa Inhibitors
-
Global Health
-
Humans
-
Incidence
-
Retrospective Studies
-
Risk Factors
-
Stroke* / epidemiology
-
Stroke* / etiology
-
Stroke* / prevention & control
Substances
-
Anticoagulants
-
Factor Xa Inhibitors